Herbal Approach to Cardiac Disease

Complementary and Integrative Therapies for Cardiovascular Disease

Volumn , Issue , 2005, Pages 86-106

  Frishman, William H ^a   Sinatra, Stephen T ^b   Moizuddin, Mohammed ^c  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 22044440762     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03002-1.50008-2     Document Type: Chapter

References (76)

1. Goldman P Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 2001, 135:594-600.
2. Sinatra ST, Frishman WH, Peterson SJ, Lin G Use of alternative/complementary medicine in treating cardiovascular disease. Cardiovascular Pharmacotherapeutics 2003, 857-874. McGraw Hill, New York. ed 2. W.H. Frishman, E.H. Sonnenblick, D.A. Sica (Eds.).
3. Tyler VE Herbs of choice. The Therapeutic Use of Phytomedicinals 1994, Pharmaceutical Product Press, New York. V.E. Tyler (Ed.).
4. Morris CA, Avorn J Internet marketing of herbal products. JAMA 2003, 290:1505-1509.
5. Garrard J, Harms S, Eberly LE, Matiak A Variations in product choices of frequently purchased herbs: caveat emptor. Arch Intern Med 2003, 163:2290-2295.
6. Straus SE Herbal medicines: what's in the bottle?. N Engl J Med 2002, 347:1997-1998.
7. DeSmet PAGM Herbal remedies. N Engl J Med 2002, 347:2046-2056.
8. Marcus DM, Grollman AP Botancial medicines: the need for new regulations. N Engl J Med 2002, 347:2073-2075.
9. Ang-Lee MK, Moss J, Yuan C-S Herbal medicines and perioperative care. JAMA 2001, 286:208-216.
10. DeSmet PAGM Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004, 76:1-17.
11. Slifman NR, Obermeyer WR, Musser SM, et al. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med 1998, 339:806-811.
12. Radford DJ, Gillies AD, Hinds JA, et al. Naturally occurring cardiac glycosides. Med J Aust 1986, 144:540.
13. Zeng X-H, Zeng X-J, Li Y-Y Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003, 92:173-176.
14. Rauwolfia alkaloids. Drug Information for the Health Care Professional 1996, I. United States Pharmacopeial Convention, Rockville, Md. ed 16. D.I. Usp (Ed.).
15. Sutter MC, Wang YX Recent cardiovascular drugs from Chinese medicinal plants. Cardiovasc Res 1993, 27:1891-1901.
16. Kawashima K, Hayakawa T, Miwa Y, et al. Structure and hypotensive activity relationships of tetrandrine derivatives in stroke-prone spontaneously hypertensive rats. Gen Pharmacol 1990, 21:343-347.
17. Physicians' Desk Reference for Nonprescription Drugs and Dietary Supplements 2004, Thomson PDR, Monvale, NJ. ed 25.
18. Kuramochi T, Chu J, Suga T Gou-teng (from Uncaria rhynchophylla Miquel) induced endothelium-dependent and independent relaxations in the isolated rat aorta. Life Sci 1994, 54:2061-2069.
19. Chang Q, Zuo Z, Harrison F, Chow MSS Hawthorn. J Clin Pharmacol 2002, 42:605-612.
20. Vibes J, Lasserre B, Gleye J, et al. Inhibition of thromboxane A2 biosynthesis in vitro by the main components of Crataegus oxyacantha (hawthorn) flower heads. Prostaglandins Leukot Essent Fatty Acids 1994, 50:173-175.
21. Shanthi S, Parasakthy K, Deepalakshmi PD, et al. Hypolipidemic activity oftincture of Crataegus in rats. Indian J Biochem Biophys 1994, 31:143-146.
22. Nasa Y, Hashizume H, Hoque AN, et al. Protective effect of Crataegus extract on the cardiac mechanical dysfunction in isolated perfused working rat heart [German]. Arzneimittelforschung 1993, 43:945-949.
23. Roddewig C, Hensel H Reaction of local myocardial blood flow in nonanesthetized dogs and anesthetized cats to the oral and parenteral administration of a Crataegus fraction (oligomere procyanidines) [German]. Arzneimittelforschung 1977, 27:1407-1410.
24. Taskov M On the coronary and cardiotonic action of crataemon. Acta Physiol Pharmacol Bulg 1977, 3:53-57.
25. Blesken R Crataegus in cardiology [German]. Fortschr Med 1992, 110:290-292.
26. Baughman KL, Bradley DJ Hawthorn extract: is it time to turn over a new leaf?. Am J Med 2003, 114:700-701.
27. Pittler MH, Schmidt K, Ernst E Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003, 114:665-674.
28. Holubarsch CJ, Colucci WS, Meinertz T, et al. Survival and prognosis: investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE)-rationale, study design, and study protocol. Eur J Heart Fail 2000, 2:431-437.
29. Schussler M, Holzl J, Fricke U Myocardial effects of flavonoids from Crataegus species. Arzneim Forsch 1995, 45:842-845.
30. Zhang W, Wojta J, Binder BR Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Arterioscler Thromb 1994, 14:1040-1046.
31. Lin SG, Zheng XL, Chen QY, et al. Effect of Panax notoginseng saponins on increased proliferation of cultured aortic smooth muscle cells stimulated by hypercholesterolemic serum. Chung Kuo Yao Li Hsueh Pao 1993, 14:314-316.
32. Ackermann RT, Mulrow CD, Ramirez G, et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med 2001, 161:813-824.
33. Silagy CA, Neil HA A meta-analysis of the effect of garlic on blood pressure. J Hypertens 1994, 12:463-468.
34. Silagy C, Neil A Garlic as a lipid lowering agent: a meta-analysis. JR Coll Physicians Lond 1994, 28:39-45.
35. Mader FH Treatment of hyperlipidaemia with garlic-powder tablets: evidence from the German Association of General Practitioners multicentric placebo-controlled, double-blind study. Arzneimittelforschung 1990, 40:1111-1116.
36. Warshafsky S, Kamer R, Sivak S Effect of garlic on total serum cholesterol. Ann Intern Med 1993, 119:599-605.
37. Stevermer JJ, Lindbloom EJ Ginkgo biloba for dementia. J Fam Pract 1998, 46:20.
38. Solomon PR, Adams F, Silver A, et al. Ginkgo for memory enhancement: a randomized controlled trial. JAMA 2002, 288:835-840.
39. Ernst E The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 2002, 136:42-53.
40. Pittler MH, Ernst E Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 2000, 108:276-281.
41. Vale S Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998, 352:36.
42. Matthews MK Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998, 50:1933-1934.
43. Rowin J, Lewis SL Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996, 46:1775-1776.
44. Gianni L, Dreitlein WB Some popular OTC herbals can interact with anticoagulant therapy. US Pharm 1998, 23:80.
45. Offord EA, Mace K, Ruffieux C, et al. Rosemary components inhibit benzo(a)pyrene-induced genotoxicity in human bronchial cells. Carcinogenesis 1995, 16:2057-2062.
46. Haraguchi H, Saito T, Okamura N, et al. Inhibition of lipid peroxidation and superoxide generation by diterpenoids from Rosmarinus officinalis. Planta Med 1995, 61:333-336.
47. Larrondo JV, Agut M, Calvo-Torras MA Antimicrobial activity of essences from labiates. Microbios 1995, 82:171-172.
48. al-Hader AA, Hasan ZA, Aqel MB Hyperglycemic and insulin release inhibiting effects of Rosmarinus officinalis. J Ethnopharmacol 1994, 43:217-221.
49. Tyler VE The honest herbal: a sensible guide to the use of herbs and related remedies 1993, Pharmaceutical Product Press, New York. ed 3.
50. Diehm C, Vollbrecht D, Amendt K, et al. Medical edema protection-clinical benefit in patients with chronic deep vein incompetence: a placebo-controlled double-blind study. Vasa 1992, 21:188-192.
51. Lang W Studies on the percutaneous absorption of 3H-aescin in pigs. Res Exp Med 1977, 169:175-187.
52. Bouskela E, Cyrino FZ, Marcelon G Possible mechanisms for the inhibitory effect of Ruscus extract on increased microvascular permeability induced by histamine in hamster cheek pouch. J Cardiovasc Pharmacol 1994, 24:281-285.
53. Bouskela E, Cyrino FZ, Marcelon G Possible mechanisms for the venular constriction elicited by Ruscus extract on hamster cheek pouch. J Cardiovasc Pharmacol 1994, 24:165-180.
54. Bouskela E, Cyrino FZ, Marcelon G Effects of Ruscus extract on the internal diameter of arterioles and venules of the hamster cheek pouch microcirculation. J Cardiovasc Pharmacol 1993, 22:221-224.
55. Berg D Venous constriction by local administration of ruscus extract [German]. Fortschr Med 1990, 108:473-476.
56. Berg D Venous tonicity in pregnancy varicose veins [German]. Fortschr Med 1992, 110:67. 71.
57. Li YP, Wang YM Evaluation of tussilagone: a cardiovascular respiratory stimulant isolated from Chinese herbal medicine. Gen Pharmacol 1988, 19:261-263.
58. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003, 289:1537-1545.
59. Fontanarosa PB, Rennie D, DeAngelis CD The need for regulation of dietary supplements: lessons from ephedra [editorial]. JAMA 2003, 289:1568-1570.
60. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002, 77:12-16.
61. Commentary: American Society for Clinical Pharmacology and Therapeutics position statement on the public health risks of ephedra. Clin Pharmacol Ther 2003, 74:403-405.
62. Gardner SF, Franks AM, Gurley BJ, et al. Effect of a multicomponent, ephedra-containing dietary supplement (Metabolife 356) on Holter monitoring and hemostatic parameters in healthy volunteers. Am J Cardiol 2003, 91:1510-1513.
63. Bent S, Tiedt TN, Odden MC, Shlipak MG The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003, 138:468-471.
64. Chan TYK, Chan JCN, Tomlinson B, et al. Chinese herbal medicines revisited: the Hong Kong perspective. Lancet 1993, 342:1532-1534.
65. Horowitz RS, Feldhaus K, Dart RC, et al. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med 1996, 156:899-903.
66. Izzo AA, Ernst E Interactions between herbal medicines and prescribed drugs. Drugs 2001, 61:2163-2175.
67. Wang Z, Gorski C, Hamman MA, et al. The effects of St. John's wort ( Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001, 70:317-326.
68. Tannergran C, Engman H, Knutson L, et al. St John's wort decreases the bioavailability of R- and S-verapamil through induction of first-pass metabolism. Clin Pharmacol Ther 2004, 75:298-309.
69. Ernst E The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, Echinacea, saw palmetto and kava. Ann Intern Med 2002, 136:42-53.
70. Mueller SC, Uehleke B, Woehling H, et al. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004, 75:546-557.
71. Knipschild P Alternative treatments: do they work?. Lancet 2000, 356:S4.
72. Lin MC, Nahin R, Gershwin E, et al. State of complementary and alternative medicine in cardiovascular, lung, and blood research: executive summary of a workshop. Circulation 2001, 103:2038-2041.
73. Vandenbroucke JP, de Craen AJM Alternative medicine: a "mirror image" for scientific reasoning in conventional medicine. Ann Intern Med 2001, 135:507-513.
74. Bent S, Ko R Commonly used herbal medicines in the United States: a review. Am J Med 2004, 116:478-485.
75. Stein CM Are herbal products dietary supplements or drugs?: an important question for public safety. Clin Pharmacol Therap 2002, 71:411-413.
76. Stys T, Stys A, Kelly P, Lawson W Trends in use of herbal and nutritional supplements in cardiovascular patients. Clin Cardiol 2004, 27:87-90.